Alight, Inc.

Alight, Inc. (NYSE: ALIT) is a leading cloud-based integrated digital human capital and business solutions provider. Fees paid by clients for services are the primary source of revenue. It provides solutions using a combination of proprietary, partner technology and a well-developed provider network.

Key Highlights

• The company reported a 3.29% increase in total revenues to USD 690 million in Q3FY21 (ended September 30, 2021) compared to USD 668 million in Q3FY20.
• ALIT reported an increase in net losses to USD 120 million in Q3FY21 from USD 39 million in Q3FY20.
• As of September 30, 2021, the company had cash and cash equivalents of USD 769 million with total outstanding debt of USD 2.88 billion, indicating a highly leveraged balance sheet.
• ALIT announced on December 16, 2021, that it would reinvent the healthcare benefits experience by combining clinical healthcare navigation with its engagement platform.
• The stock is now trading between its key short-term (50-day) and long-term (200-day) DMA support levels, with the RSI Index at 49.50.
• Stock is leaning towards the lower band of the 52-week range of USD 8.46 to USD 14.51.
• The stock remained relatively stable throughout the year. However, in the past three months, ALIT corrected ~9.03%.

Technical Price Chart (as of December 22, 2021). Analysis by Kalkine

Conclusion: Considering the increase in losses, margins pressure, and technical indicators, we recommend an "Watch" rating on the stock at the closing price of USD 10.48, up 0.29% as of December 22, 2021.

*The reference data in this report has been partly sourced from REFINITIV.

Biomerica, Inc.

Biomerica, Inc. (NASDAQ: BMRA) operates as a  biomedical technology company, which develops, patents, manufactures, and sells diagnostic and therapeutic solutions for the early identification and monitoring of chronic diseases and other illnesses.

Key Highlights

• The company reported YoY growth of 10.31% in net sales to USD 1.26 million in Q1FY22 (ended August 31, 2021) compared to USD 1.14 million in Q1FY21.
• BMRA's net loss reduced to USD 1.54 million during Q1FY22 vs. USD 1.89 million in Q1FY21.
• As of August 31, 2021, the company had cash and cash equivalents of USD 5.00 million and no outstanding debt.
• Negative Net Margin of 122.3% in Q1FY22 vs. industry median of 6.1%.
• As per its preliminary release on December 16, 2021, BMRA estimates revenue of ~USD 4.6 million in the Q2FY22, a 238% YoY growth over revenue of ~USD 1.4 million in the Q2FY21.
• On November 19, 2021, BMRA announced that Dr. Brooks Cash, one of the well-known leaders in gastroenterology medicine, has volunteered to chair BMRA's newly formed Colorectal Cancer Scientific Advisory Board (SAB).
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, a bearish indicator.
• The stock is leaning towards the lower end of its 52-week range of USD 3.30 to USD 8.15.
• BMRA's stock price decreased 8.68% and 4.12% in the past one and three months, respectively.

Technical Price Chart (as of December 22, 2021). Analysis by Kalkine

Conclusion: Considering the topline growth, long-term profitability issues, technical indicators, and associated risks, we recommend a "Watch" rating on the stock at the current price of USD 4.42, up 1.14%, as of December 22, 2021, 03:55 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.